Icon

ZINACEF IN PLASTIC CONTAINER (nda050643)- (EQ 15MG BASE/ML,EQ 30MG BASE/ML)

CEFUROXIME SODIUM PAI HOLDINGS PHARM
EQ 15MG BASE/ML,EQ 30MG BASE/ML
No No
Expired Expired
None None
None No
ZINACEF isindicatedforthetreatmentofpatientswithinfectionscausedbysusceptiblestrains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilusinfluenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcusaureus(penicillinase-and non-penicillinase-producingstrains), Streptococcus pyogenes, and Escherichia coli. 2. Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. 3. Skin and Skin-Structure Infections caused by Staphylococcus aureus(penicillinase-and non-penicillinase-producing strains), Streptococcus pyogenes, Escherichia coli, Klebsiella spp., and Enterobacter spp. 4. Septicemia caused by Staphylococcus aureus (penicillinase-and non-penicillinase-producing strains), Streptococcuspneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. 5. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis, and Staphylococcusaureus (penicillinase-and non-penicillinase-producingstrains). 6. Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase-and non-penicillinase-producingstrains) in both males and females. 7. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase-and nonpenicillinase-producingstrains).
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 15MG BASE/ML ** ** - - -
EQ 30MG BASE/ML ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.